Analysis of Pharmacokinetic and Pharmacodynamic Interactions Between Chlorpromazine and Risperidone via Simultaneous Measurement of Multiple Receptor Occupancy in the Rat Brain

<b>Background/Objectives:</b> Combination therapy for schizophrenia may exacerbate side effects mediated by multiple brain receptors. This study aimed to elucidate the pharmacodynamic and pharmacokinetic interactions between chlorpromazine and risperidone. We investigated dopamine 2 (D<sub>2</sub>), serotonin 2A (5-HT<sub>2A</sub>), histamine 1 (H<sub>1</sub>), and muscarinic acetylcholine (mACh) receptor occupancy in the brain as well as pharmacokinetic interactions after oral administration of chlorpromazine and risperidone in rats. <b>Methods:</b> Rats were orally administered chlorpromazine, risperidone, or their combination. A tracer cocktail solution was injected intravenously to measure multiple receptor occupancies simultaneously. Tracer and drug concentrations in the brain tissue and plasma were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). <b>Results:</b> Receptor occupancy increased in a dose-dependent manner. The doses required for 70% D<sub>2</sub> receptor occupancy were 4.5 mg/kg for chlorpromazine and 1.5 mg/kg for risperidone. Co-administration of chlorpromazine (4.5 mg/kg) and risperidone (1.5 mg/kg) resulted in an increase in D<sub>2</sub> and 5-HT<sub>2A</sub> receptor occupancy to approximately 90%. Risperidone alone caused a transient increase in H<sub>1</sub> receptor occupancy to 80%, while co-administration increased mACh receptor occupancy to 60%. Co-administration with chlorpromazine significantly increased the plasma concentrations of risperidone and its metabolite, paliperidone, and decreased the oral clearance of risperidone by 5.9-fold. <b>Conclusions:</b> Co-administration of chlorpromazine and risperidone increases the occupancy of D<sub>2</sub>, 5-HT<sub>2A</sub>, and mACh receptors in the rat brain and increases the plasma concentrations of risperidone and paliperidone, suggesting a potential risk of enhanced adverse effects due to both pharmacokinetic and pharmacodynamic interactions involving target and non-target brain receptors.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-01-06
DOI
https://doi.org/10.3390/biomedicines14010118
Primary Topic
Neurotransmitter Receptor Influence on Behavior
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Analysis of Pharmacokinetic and Pharmacodynamic Interactions Between Chlorpromazine and Risperidone via Simultaneous Measurement of Multiple Receptor Occupancy in the Rat Brain

Takashi Okura, Gaku Akashita, Eriko Nakatani, Shimako Tanaka
Biomedicines
Neurotransmitter Receptor Influence on Behavior
article

Analysis of Pharmacokinetic and Pharmacodynamic Interactions Between Chlorpromazine and Risperidone via Simultaneous Measurement of Multiple Receptor Occupancy in the Rat Brain

Takashi Okura, Gaku Akashita, Eriko Nakatani, Shimako Tanaka
article en

Abstract

<b>Background/Objectives:</b> Combination therapy for schizophrenia may exacerbate side effects mediated by multiple brain receptors. This study aimed to elucidate the pharmacodynamic and pharmacokinetic interactions between chlorpromazine and risperidone. We investigated dopamine 2 (D<sub>2</sub>), serotonin 2A (5-HT<sub>2A</sub>), histamine 1 (H<sub>1</sub>), and muscarinic acetylcholine (mACh) receptor occupancy in the brain as well as pharmacokinetic interactions after oral administration of chlorpromazine and risperidone in rats. <b>Methods:</b> Rats were orally administered chlorpromazine, risperidone, or their combination. A tracer cocktail solution was injected intravenously to measure multiple receptor occupancies simultaneously. Tracer and drug concentrations in the brain tissue and plasma were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). <b>Results:</b> Receptor occupancy increased in a dose-dependent manner. The doses required for 70% D<sub>2</sub> receptor occupancy were 4.5 mg/kg for chlorpromazine and 1.5 mg/kg for risperidone. Co-administration of chlorpromazine (4.5 mg/kg) and risperidone (1.5 mg/kg) resulted in an increase in D<sub>2</sub> and 5-HT<sub>2A</sub> receptor occupancy to approximately 90%. Risperidone alone caused a transient increase in H<sub>1</sub> receptor occupancy to 80%, while co-administration increased mACh receptor occupancy to 60%. Co-administration with chlorpromazine significantly increased the plasma concentrations of risperidone and its metabolite, paliperidone, and decreased the oral clearance of risperidone by 5.9-fold. <b>Conclusions:</b> Co-administration of chlorpromazine and risperidone increases the occupancy of D<sub>2</sub>, 5-HT<sub>2A</sub>, and mACh receptors in the rat brain and increases the plasma concentrations of risperidone and paliperidone, suggesting a potential risk of enhanced adverse effects due to both pharmacokinetic and pharmacodynamic interactions involving target and non-target brain receptors.

BiomedicinesVol. 14(1)
Teikyo University (JP)
Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 94%
Neurotransmitter Receptor Influence on Behavior
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.